Robin DiFrancesco

Summary

Affiliation: University at Buffalo
Country: USA

Publications

  1. pmc Antiretroviral bioanalysis methods of tissues and body biofluids
    Robin DiFrancesco
    HIV Clinical Pharmacology Quality Assurance and HIV Clinical Pharmacology Research Programs, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences, 701 Ellicott Street, Buffalo, NY 14203, USA
    Bioanalysis 5:351-68. 2013
  2. ncbi request reprint Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry
    Robin DiFrancesco
    Department of Pharmacy Practice, University at Buffalo, NY 14260, United States
    J Pharm Biomed Anal 44:1139-46. 2007
  3. pmc Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial
    Robin DiFrancesco
    Department of Pharmacy Practice, SUNY at Buffalo, Buffalo, NY, USA
    Ther Drug Monit 32:458-66. 2010
  4. ncbi request reprint Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry
    Robin DiFrancesco
    Department of Pharmacy Practice, University at Buffalo, 311 Hochstetter Hall, Buffalo, NY 14260, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 852:545-53. 2007
  5. ncbi request reprint Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application
    Kim Keil
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
    Ther Drug Monit 29:103-9. 2007
  6. ncbi request reprint Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir
    Niamh Higgins
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Am J Addict 16:488-94. 2007
  7. ncbi request reprint Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users
    Robin DiFrancesco
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
    J Pharm Biomed Anal 44:188-95. 2007
  8. ncbi request reprint Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring
    Judianne Slish
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Ther Drug Monit 29:560-5. 2007
  9. doi request reprint Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients
    Kathleen M Tornatore
    Department of Pharmacy Practice, Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA Division of Nephrology, Department of Medicine, School of Medicine and Biomedical Sciences, Erie County Medical Center, University at Buffalo, Buffalo, NY, USA
    J Clin Pharmacol 53:1039-47. 2013
  10. pmc Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks
    Olanrewaju Okusanya
    Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 317 Hochstetter Hall, Amherst, NY 14260, USA
    Antimicrob Agents Chemother 51:1822-6. 2007

Collaborators

Detail Information

Publications24

  1. pmc Antiretroviral bioanalysis methods of tissues and body biofluids
    Robin DiFrancesco
    HIV Clinical Pharmacology Quality Assurance and HIV Clinical Pharmacology Research Programs, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences, 701 Ellicott Street, Buffalo, NY 14203, USA
    Bioanalysis 5:351-68. 2013
    ..40% of the assays provided complete intra- and inter-assay validation data, but only 9% of publications provided any stability data with even less for the prevalent ARV in treatments...
  2. ncbi request reprint Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry
    Robin DiFrancesco
    Department of Pharmacy Practice, University at Buffalo, NY 14260, United States
    J Pharm Biomed Anal 44:1139-46. 2007
    ..The method successfully measured LPV concentrations in CSF that were previously undetectable by HPLC as well as UF from protein binding studies...
  3. pmc Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial
    Robin DiFrancesco
    Department of Pharmacy Practice, SUNY at Buffalo, Buffalo, NY, USA
    Ther Drug Monit 32:458-66. 2010
    ..The application of some of these findings may also be relevant to single-center studies or clinical TDM programs within a hospital...
  4. ncbi request reprint Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry
    Robin DiFrancesco
    Department of Pharmacy Practice, University at Buffalo, 311 Hochstetter Hall, Buffalo, NY 14260, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 852:545-53. 2007
    ..1 by 30 mm (Milford, MA) column. Detection was achieved in positive mixed reaction monitoring mode on a triple quadrupole mass spectrometer...
  5. ncbi request reprint Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application
    Kim Keil
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
    Ther Drug Monit 29:103-9. 2007
    ..During 2 years, more than 100 batches of analyses have been performed and have proved the method is rugged, specific, and accurate. This assay method is currently used in the authors' clinical research program in TDM...
  6. ncbi request reprint Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir
    Niamh Higgins
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Am J Addict 16:488-94. 2007
    ..These data indicate that chronic HIV treatment may be assisted with plasma concentration monitoring to identify those patients who may require dosage modification and/or regimen adjustment in order to optimize antiretroviral effects...
  7. ncbi request reprint Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users
    Robin DiFrancesco
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
    J Pharm Biomed Anal 44:188-95. 2007
    ..Use of this combined BUP and ARV plasma concentration monitoring approach for a representative patient receiving BUP, atazanavir and efavirenz demonstrated its clinical application...
  8. ncbi request reprint Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring
    Judianne Slish
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Ther Drug Monit 29:560-5. 2007
    ..Further work is needed to assess the optimal dosing regimen when using LPV in HIV-infected substance users...
  9. doi request reprint Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients
    Kathleen M Tornatore
    Department of Pharmacy Practice, Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA Division of Nephrology, Department of Medicine, School of Medicine and Biomedical Sciences, Erie County Medical Center, University at Buffalo, Buffalo, NY, USA
    J Clin Pharmacol 53:1039-47. 2013
    ..0009]. Female RTR had slower cyclosporine clearance and lower ABCB1 gene expression in PBMC suggesting reduced efflux activity and greater intracellular drug exposure. ..
  10. pmc Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks
    Olanrewaju Okusanya
    Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 317 Hochstetter Hall, Amherst, NY 14260, USA
    Antimicrob Agents Chemother 51:1822-6. 2007
    ..The nature of the secondary peaks may be an important consideration for the interpretation of amprenavir plasma concentrations during therapeutic drug monitoring...
  11. pmc Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders
    Qing Ma
    Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14203, USA
    Ther Drug Monit 33:309-14. 2011
    ..The objective of this study was to utilize therapeutic drug monitoring to compare efavirenz (EFV) and protease inhibitor pharmacokinetics in patients with and without SRDs...
  12. doi request reprint Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients
    Kathleen M Tornatore
    Pharmacotherapy Research Center, Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
    J Clin Pharmacol 53:285-93. 2013
    ..Limited mycophenolic acid (MPA) data are available comparing racial influence on mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) pharmacokinetics...
  13. pmc Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients
    Qing Ma
    Center for Human Experimental Therapeutics, Clinical and Translational Sciences Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    J Neurovirol 19:254-60. 2013
    ..7 to 15.9 h (pā€‰=ā€‰0.002) were observed. The results suggested that co-administration of CEP-1347 with ATV/RTV in HIV-infected patients might result in limited impact on ATV but not on RTV pharmacokinetics...
  14. pmc Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals
    Gene D Morse
    Adult ACTG Pharmacology Support Laboratory, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, University at Buffalo, Amherst, NY 14260, USA
    Antimicrob Agents Chemother 49:3373-81. 2005
    ..7 to 1.0; P = 0.042). African-American non-Hispanics had higher day 14 efavirenz AUCs than white non-Hispanics. We conclude that EFV lowered APV AUCs, but nelfinavir, indinavir, or ritonavir compensated for EFV induction...
  15. ncbi request reprint Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV
    Qing Ma
    University at Buffalo, Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, NY, USA
    Pharmacogenomics 8:227-35. 2007
    ..We examined MDR1 single nucleotide polymorphisms in a cohort of patients in whom therapeutic drug monitoring is ongoing through a research protocol...
  16. ncbi request reprint Determination of tipranavir in human plasma by reverse phase liquid chromatography with UV detection using photodiode array
    Kim Keil
    Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
    Ther Drug Monit 28:512-6. 2006
    ..390 microg/mL with an interday variation in control value ranging from 2.9 to 4.6%. The method is being used in a clinical therapeutic drug monitoring program that is ongoing in our laboratory...
  17. pmc Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratories
    Robin DiFrancesco
    HIV Clinical Pharmacology Research Program, Translational Pharmacology Research Core, Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York Frontier Science Technology and Research Foundation, Amherst, New York RTI International, Research Triangle Park, North Carolina New York State Department of Health, Albany, New York
    Ther Drug Monit 35:631-42. 2013
    ..Significant associations were present between magnitude of error and CPL (Kruskal-Wallis P < 0.001) and antiretroviral (Kruskal-Wallis P < 0.001)...
  18. doi request reprint Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients
    Kathleen M Tornatore
    Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14260 1200, USA
    J Clin Pharmacol 51:1213-22. 2011
    ..The results support differential MPA dosing and the role of therapeutic drug monitoring in addition to considering the influence of renal function and concurrent immunosuppressives on MPA and MPAG pharmacokinetics...
  19. ncbi request reprint Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma
    Kim Keil
    Department of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14260, USA
    Ther Drug Monit 25:340-6. 2003
    ..1 to 0.2 microg/mL with an interday variation in CV ranging from 3.5% to 10.4%. The method is being applied to a TDM program that is currently being implemented in the authors' laboratory...
  20. ncbi request reprint Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals
    Patrick F Smith
    Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 219 Cooke Hall, Buffalo, NY 14260, USA
    Clin Pharmacokinet 44:99-109. 2005
    ..Our objective was to characterise the population pharmacokinetics of delavirdine in HIV-infected patients who participated in the adult AIDS Clinical Trials Group (ACTG) 260 and 261 studies...
  21. ncbi request reprint Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpoints
    Robin DiFrancesco
    Department of Pharmacy Practice, University at Buffalo, Buffalo, New York 14260, USA
    HIV Clin Trials 7:203-9. 2006
    ..To achieve this goal, a tutorial was designed to improve the accuracy and completeness of data collected in ACTG pharmacology protocols...
  22. ncbi request reprint Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers
    Desiree L Tomilo
    School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
    Pharmacotherapy 26:341-6. 2006
    ..To determine whether the pharmacokinetics of atazanavir, a protease inhibitor used to treat human immunodeficiency virus (HIV) infection, are altered by its coadministration with lansoprazole, a proton pump inhibitor...
  23. ncbi request reprint Simultaneous determination of cortisol, dexamethasone, methylprednisolone, prednisone, prednisolone, mycophenolic acid and mycophenolic acid glucuronide in human plasma utilizing liquid chromatography-tandem mass spectrometry
    Robin DiFrancesco
    School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY14260 1200, United States
    J Chromatogr B Analyt Technol Biomed Life Sci 859:42-51. 2007
    ..76% and 9.57% for all analytes. This assay offers a versatile, unique method for multi-analyte immunosuppressive determinations during combination immunosuppression...
  24. ncbi request reprint Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry
    Valerie A Frerichs
    Pharmacotherapy Research Center, Core Analytical Laboratory, Department of Pharmacy Practice, University at Buffalo, State University of New York, Room 317 Hochstetter Hall, Buffalo, NY 14260 1200, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 787:393-403. 2003
    ..The evolution of complex drug interactions assessments and the clinical use of therapeutic drug monitoring for these antiretrovirals will be a potential immediate application of this method...